Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452 is registered in ClinicalTrials.gov with Vedanta Biosciences, Inc. as lead sponsor.

NCT NCT06237452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06237452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Lead sponsor
Vedanta Biosciences, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
May 20, 2024
Completion date
October 31, 2027
Enrollment
852 (estimated)
Sites
215

Conditions

As the registry lists them; a condition with its own page is linked.

c. diff infection, c.difficile diarrhea, cdi, clostridioides difficile infection, clostridioides difficile infection recurrence, clostridium difficile, clostridium difficile infection recurrence, clostridium difficile infections, diarrhea infectious, recurrent clostridium difficile infection